The FDA recommends pausing vaccination with Johnson & Johnson’s formula against coronavirus after six cases of thrombosis in the EU

United States will suspend evacuation with the Johnson & Johnson formula against COVID-19 on the recommendation of the FDA, according to which there are six cases of thrombosis between the 6.8 million doses applied in the country.

Sanitary regulators will hold a meeting of these markets to analyze the data. “As soon as this process is complete, we recommend this break. It’s important to ensure that the medical attention testing community is aware of the potential of these adverse events and can plan to have a unique treatment required with this type of blood clots, ”the FDA said in a statement.

The organism details that its six cases have been detected as “a rare and serious type of blood clot in people after receiving the vaccine”, which has now been “extremely unusual”.

Federal distribution channels, including the massive evacuation centers, will start using the pharmacy temporarily, and it is hoped that the states and other providers will do the same. If you are taking precautionary measures to confirm this, there is no corner between the formula and the thrombosis cases.

Europe has registered similar situations with the Oxford / AstraZeneca vaccine. Hasta now, the investigators detect a relationship with the vaccine, possibly a reaction of the immunological system, but note that the benefits of the doses followed by majors to the giants, all over the major adult population.

The J&J vaccine, like AstraZeneca’s, works with viral vector technology. Here is the explanation of the CDC: “Contains a modified version of another virus (the vector) for important instructions on our cells”.

News on development …